2 326

Cited 143 times in

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib

 Byoung Chul Cho  ;  Chong-Kun Im  ;  Joo Hang Kim  ;  Hoguen Kim  ;  Joo Hyuk Sohn  ;  Sang-Joon Shin  ;  Yu Jin Kim  ;  Hye Jin Choi  ;  Jong Pil Park  ;  Joon Chang  ;  Se Kyu Kim  ;  Moo-Suk Park 
 JOURNAL OF CLINICAL ONCOLOGY, Vol.25(18) : 2528-2533, 2007 
Journal Title
Issue Date
Antineoplastic Agents/therapeutic use* ; Biomarkers, Tumor/analysis ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; Drug Resistance, Neoplasm ; Erlotinib Hydrochloride ; Female ; Gefitinib ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use* ; Quinazolines/therapeutic use* ; Survival Rate ; Treatment Outcome
PURPOSE: This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib. PATIENTS AND METHODS: The study included stage IIIB/IV recurrent or metastatic NSCLC patients who received two or three prior chemotherapy regimens and showed progressive disease within 4 months of gefitinib therapy discontinuation. Patients received erlotinib 150 mg/d until disease progression or unacceptable toxicity. Epidermal growth factor receptor (EGFR) mutations and other genetic abnormalities were analyzed from available tumor samples. RESULTS: Patient and disease characteristics (N = 21) included median age 56 years; number of prior chemotherapy regimens (three; n = 11); female sex (n = 11); adenocarcinoma (n = 15); and never-smoker status (n = 11). Among the 17 patients with tumor samples available, EGFR mutations were detected in five. The disease control rate (DCR) and response rate (RR) for all patients were 28.6% and 9.5%, respectively. The median duration of disease control was 125 days. The median time to progression and overall survival were 60 days and 158 days, respectively. Patients who had stable disease (SD) while receiving gefitinib showed significantly higher DCR (75% v 17.6% in non-SD patients; P = .050) and RR (50.0% v 0% in non-SD patients; P = .029). Among 17 patients with biomarker results available, those lacking EGFR mutations who had SD while receiving gefitinib showed significantly higher DCR and RR. CONCLUSION: Erlotinib seems to be a potential therapeutic option for the treatment of advanced NSCLC patients with wild-type EGFR who had SD while receiving gefitinib.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Yoo Jin(김유진)
Kim, Joo Hang(김주항)
Kim, Ho Keun(김호근)
Park, Moo Suk(박무석) ORCID logo https://orcid.org/0000-0003-0820-7615
Park, Jong Pil(박종필) ORCID logo https://orcid.org/0000-0002-6525-3012
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Im, Chong Kun(임종근)
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.